2020
Life Sciences Year in Review
Over the past year, the life sciences industry has persevered through intense adversity. At Goodwin, we are incredibly proud to serve as legal counsel and trusted business advisors to our extraordinary clients across the life sciences ecosystem.
This Year in Review recaps the resilience of our full-service practice, driven by the trust clients have placed in our global team of industry-leading practitioners.
We thank you for your ongoing partnership and sincerely look forward to 2021 and our continued work for our inspiring clients.
North Asia: BeiGene’s Global Strategic Oncology Collaboration with Amgen
Life Sciences Team of the Year (2020)
Global Market Recognition
Notable Deals
We are proud to have counseled our clients on some of the most notable deals of 2020. Click on the logos below to learn more about some of our highlights.
Learn More
Explore additional information about our practice, including our full list of press releases, webinars, awards and rankings, thought leadership and upcoming events:
This informational piece, which may be considered advertising under the ethical rules of certain jurisdictions, is provided on the understanding that it does not constitute the rendering of legal advice or other professional advice by Goodwin Procter or its lawyers. Prior results do not guarantee a similar outcome. Goodwin Procter is an international legal practice carried on by Goodwin Procter LLP and its affiliated entities. For further information about our offices and the regulatory regimes that apply to them, please refer to
© 2021 Goodwin Procter. All rights reserved
Life Sciences Practice Page
Life Sciences Perspectives Blog
Goodwin + KPMG @ JP Morgan Symposium
Goodwin’s fully-integrated Life Sciences practice is designed to help clients navigate the rapidly evolving demands by providing a unique “one-stop-shop” service, allowing us to seamlessly advise through all stages of the corporate lifecycle while guiding our clients’ strategic and business goals.
We are proud to have a dedicated team of life sciences lawyers located in the major innovation hubs across the United States, Europe and Asia, giving our team the unique ability to advise clients when and where our services are needed.
Healthcare
Formalized Four New Practices
Added 26 New Lawyers Across Nine Offices
Our Growth
45+ Collaboration Transactions for Over $8.3 Billion
55+ Follow-On Transactions* for Over $14 Billion
*Issuers and underwriters
50+ M+A Transactions for Over $58.5 Billion
150+ Venture Capital Transactions for Over $8.5 Billion
By the Numbers
25+ IPO Transactions* for Over $7.3 Billion
PropSci
Special Purpose Acquisition Companies (SPACs)
Late Stage
Drug Development
Biotechnology
Law Firm of the Year (2021)
M+A Deal of the Year Finalist (2020)
Counsel to EQRX on its launch and $200 million Series A financing to create innovative medicines at dramatically lower prices for people, healthcare systems and society.
Counsel to Relay Therapeutics on its $460 million upsized initial public offering, the fifth largest biotechnology IPO of 2020.
Counsel to Alnylam Pharmaceuticals on its $2 billion strategic financing collaboration with Blackstone to support Alnylam’s advancement of innovative RNA interference (RNAi) medicines for patients suffering from a range of debilitating diseases.
Counsel to AbCellera on its $555.5 million initial public offering, one of the largest biotechnology IPOs in history.
Counsel to KaNDy Therapeutics on its acquisition by Bayer for a total value of up to $875 million. This deal is recognized as the largest European Life Sciences M+A transaction of 2020.
Counsel to Moderna since its inception ten years ago. In 2020, we advised on all legal and governance aspects of Moderna’s development and global distribution of its 1273-COVID vaccine.
Counsel to the underwriters on Royalty Pharma’s $2.5 billion initial public offering, the largest IPO in the history of the healthcare and life sciences industries.
Counsel to longtime client MyoKardia on its $13.1 billion sale to Bristol Myers Squibb. MyoKardia’s mission is to discover and develop targeted therapies for the treatment of serious cardiovascular disease.
goodwinlaw.com/Legal-Notices
Hover over and click on the photos to learn more.
We are proud to have counseled our clients on some of the most notable deals of 2020. Tap on the logos below to learn more about some of our highlights.
